Product
AI AGENTS
AI APPLICATIONS
OTHERS
Solutions
INDUSTRIES
USE CASES
Pricing
Resources
EXPLORE
ENGAGE
SUPPORT & SERVICES
About
PatSnap Eureka Platform
Agents for IP
Agents for Engineering
Agents for Life Sciences
Agents for Materials
PatSnap Eureka Desktop
NEWAnalytics
IP IntelligenceSynapse
Biopharma IntelligenceBio
Biosequence Search and AnalysisChemical
Chemical Structure Search and AnalysisOpen Platform
NEWProfessional Services
Customer Stories
Newsroom
Blog
Global Innovation Report
Glossary
Webinars & Training
Frontier
User Community
R&D Benchmark Calculator
Trust and Security
PatentBench
NEWLLM
Help center
Careers
Access to over 2,000,000,000 structured data points around patents, science, litigation, and tech sectors
Innovate 75% faster at 25% less cost
Cloud or on-prem for maximum privacy and control
Trusted by more than 18,000 innovators worldwide
To use , click the vertification button in the email we sent to [email protected].
This helps keep your account secure.
You should receive it shortly. Don’t forget to check your spam folder.
Unlock professional features and history
Already have an account? Log In
To start using PatSnap Eureka, click the verification button in the email we sent to .
This helps keep your account secure.
Haven't received it? Check your spam folder.
Thoughtfully curated series offering valuable insights for innovation professionals
Article | Report Master patent search for chemically modified sequences like GalNAc & LNA. Discover how Patsnap Eureka Life Science's AI platform reduces FTO risk. Book a demo today.
Article | Report Monitor competitor monoclonal antibody patents with AI. Get proactive insights, extract deep data, and compare assets for strategic mAb competitive intelligence. Request a demo.
Article | Report IP professionals need biosequence search & patent legal status. Patsnap Eureka Life Science unifies both for FTO, prior art, and defensible IP opinions. Book a demo.
Article | Report How does tezepelumab's TSLP inhibition differ from IL-33 blockade (itepekimab, astegolimab) in phenotype coverage, clinical efficacy, and atopic march pipeline potential?
Article | Report APOE ε4 genotype ARIA risk multipliers and clinical decision framework for lecanemab and donanemab prescribing in Alzheimer's disease treatment.
Article | Report How do FXIa inhibitors asundexian and milvexian compare to apixaban and rivaroxaban on bleeding risk and efficacy? Patent and clinical trial evidence analysed.
Article | Report How do Tarlatamab and Elranatamab differ from gamma-delta T-cell therapies in TME penetration, cytokine release risk, and MHC-I resistance? A mechanistic analysis.
Article | Report How do patient population differences and I² heterogeneity (0%–95%) across five Lecanemab/Donanemab trials affect meta-analysis reliability and clinical applicability?
Article | Report How do FXR agonists, THRβ agonists, and ACC inhibitors differ in targeting MASH? Mechanistic analysis and pipeline combination strategy evidence.
Article | Report Meta-analysis comparing lecanemab and donanemab vs placebo across ADCOMS, CDR-SB, ADAS-Cog 14, and amyloid PET in early Alzheimer's disease. Full effect sizes, CIs, and heterogeneity data.
Article | Report DESTINY-Breast04's updated 32-month follow-up confirms T-DXd's OS and PFS benefit in HER2-low mBC, with key findings on ILD safety, ER-low subgroups, and ADC positioning.
Article | Report Analyse THRβ agonist selectivity SAR, hepatic uptake optimisation, ADME/PK profiles, and structural strategies that reduce cardiac and bone off-target effects vs non-selective THR agonists.
Article | Report Analyse asundexian's oxopyridine scaffold, sub-nanomolar FXIa potency (Ki 0.26 nM), >38,000-fold selectivity over Factor Xa and thrombin, and structural differentiation from DOAC chemical series.
Article | Report Voclosporin vs cyclosporine A: structural modifications, SAR patterns, nephrotoxicity reduction data, ADME/PK profile, and pharmacophore features in IgA nephropathy.
Article | Report Deep-dive into Tarlatamab (AMG 757) BiTE architecture: DLL3-binding SAR, CD3 affinity tuning, bivalency data, and how it outperforms earlier DLL3 bispecifics.